Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System
International Journal of Clinical Pharmacy · 28.04.2026 · 48 (4) · 1703-1713
DOI: 10.1007/s11096-026-02153-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 28.04.2026. Verfasst von Hai-Yu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The second Hospital of Shanxi Medical University, Shanxi, 030000, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Disseminated Intravascular Coagulation, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanxi Province, State Key Laboratory of Neurology and Oncology Drug Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The second Hospital of Shanxi Medical University, Shanxi, 030000, China.
- School of Pharmacy, Shanxi Medical University, Shanxi, 030000, China.
- State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
- The second Hospital of Shanxi Medical University, Shanxi, 030000, China. ruiganghou9966@163.com.
- School of Pharmacy, Shanxi Medical University, Shanxi, 030000, China. ruiganghou9966@163.com.
- Medical Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Medical University, Taiyuan, 030000, China. ruiganghou9966@163.com.
Förderung
- Natural Science Foundation of Shanxi Province
- State Key Laboratory of Neurology and Oncology Drug Development
Zitieren
APA
Liu, H. Y., Qu, M. Y., Wang, S. Y., Liu, J. J., Wang, S. Y., & Hou, R. G. (2026). Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System. International Journal of Clinical Pharmacy, 48(4), 1703-1713. https://doi.org/10.1007/s11096-026-02153-9
Vancouver
Liu HY, Qu MY, Wang SY, Liu JJ, Wang SY, Hou RG. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System. International Journal of Clinical Pharmacy. 2026;48(4):1703-1713. doi:10.1007/s11096-026-02153-9
BibTeX
@article{Liu2026,
author = {Liu, Hai-Yu and Qu, Mei-Yu and Wang, Shu-Yun and Liu, Jun-Jin and Wang, Si-Yang and Hou, Rui-Gang},
title = {Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System},
journal = {International Journal of Clinical Pharmacy},
year = {2026},
volume = {48},
number = {4},
pages = {1703--1713},
doi = {10.1007/s11096-026-02153-9}
}
EUVIMED